AusCann Group Holdings Limited announced that it has completed the manufacturing and testing of its proprietary cannabinoid-based hard-shell capsules in a low-dose presentation. On 18 December 2019 the Company announced the successful manufacturing, testing and release of a commercial-sized batch of the cannabinoid-based capsules. On February 17, 2020, AusCann announced the successful manufacturing, testing and release of a low-dose presentation of the capsules, at commercial scale. The Therapeutic Goods Administration's (TGA) guidance document1 suggests that the general principle for medicinal cannabis dosing should be "start low, go slow". It is therefore critical to provide doctors and their patients with a controlled-dose formulation in different doses to enable dose titration and personalised treatment.